BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

661 related articles for article (PubMed ID: 16439621)

  • 21. Dermatological findings in 61 mutation-positive individuals with cardiofaciocutaneous syndrome.
    Siegel DH; McKenzie J; Frieden IJ; Rauen KA
    Br J Dermatol; 2011 Mar; 164(3):521-9. PubMed ID: 21062266
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cardiofaciocutaneous syndrome, a Noonan syndrome related disorder: clinical and molecular findings in 11 patients].
    Carcavilla A; García-Miñaúr S; Pérez-Aytés A; Vendrell T; Pinto I; Guillén-Navarro E; González-Meneses A; Aoki Y; Grinberg D; Ezquieta B
    Med Clin (Barc); 2015 Jan; 144(2):67-72. PubMed ID: 25194980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Molecular genetic diagnostics in syndromes associated with the RAS/MAPK signalling pathway].
    Molven A; Søvik O; von der Lippe C; Steine SJ; Njølstad PR; Houge G; Prescott TE
    Tidsskr Nor Laegeforen; 2009 Nov; 129(22):2358-61. PubMed ID: 19935936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Constitutive activation of B-Raf in the mouse germ line provides a model for human cardio-facio-cutaneous syndrome.
    Urosevic J; Sauzeau V; Soto-Montenegro ML; Reig S; Desco M; Wright EM; Cañamero M; Mulero F; Ortega S; Bustelo XR; Barbacid M
    Proc Natl Acad Sci U S A; 2011 Mar; 108(12):5015-20. PubMed ID: 21383153
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Germline mutation in BRAF codon 600 is compatible with human development: de novo p.V600G mutation identified in a patient with CFC syndrome.
    Champion KJ; Bunag C; Estep AL; Jones JR; Bolt CH; Rogers RC; Rauen KA; Everman DB
    Clin Genet; 2011 May; 79(5):468-74. PubMed ID: 20735442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardio-facio-cutaneous syndrome: does genotype predict phenotype?
    Allanson JE; Annerén G; Aoki Y; Armour CM; Bondeson ML; Cave H; Gripp KW; Kerr B; Nystrom AM; Sol-Church K; Verloes A; Zenker M
    Am J Med Genet C Semin Med Genet; 2011 May; 157C(2):129-35. PubMed ID: 21495173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mutational and functional analysis in human Ras/MAP kinase genetic syndromes.
    Tidyman WE; Rauen KA
    Methods Mol Biol; 2010; 661():433-47. PubMed ID: 20812000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Human development and the RAS/MAPK pathway].
    Aoki Y; Matsubara Y
    Seikagaku; 2007 Jan; 79(1):34-8. PubMed ID: 17319511
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of germline mutations in the Ras/MAPK signaling pathway on adaptive behavior: cardiofaciocutaneous syndrome and Noonan syndrome.
    Pierpont EI; Pierpont ME; Mendelsohn NJ; Roberts AE; Tworog-Dube E; Rauen KA; Seidenberg MS
    Am J Med Genet A; 2010 Mar; 152A(3):591-600. PubMed ID: 20186801
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New BRAF knockin mice provide a pathogenetic mechanism of developmental defects and a therapeutic approach in cardio-facio-cutaneous syndrome.
    Inoue S; Moriya M; Watanabe Y; Miyagawa-Tomita S; Niihori T; Oba D; Ono M; Kure S; Ogura T; Matsubara Y; Aoki Y
    Hum Mol Genet; 2014 Dec; 23(24):6553-66. PubMed ID: 25035421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. C-type natriuretic peptide improves growth retardation in a mouse model of cardio-facio-cutaneous syndrome.
    Inoue SI; Morozumi N; Yoshikiyo K; Maeda H; Aoki Y
    Hum Mol Genet; 2019 Jan; 28(1):74-83. PubMed ID: 30239744
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Germline KRAS and BRAF mutations in cardio-facio-cutaneous syndrome.
    Niihori T; Aoki Y; Narumi Y; Neri G; Cavé H; Verloes A; Okamoto N; Hennekam RC; Gillessen-Kaesbach G; Wieczorek D; Kavamura MI; Kurosawa K; Ohashi H; Wilson L; Heron D; Bonneau D; Corona G; Kaname T; Naritomi K; Baumann C; Matsumoto N; Kato K; Kure S; Matsubara Y
    Nat Genet; 2006 Mar; 38(3):294-6. PubMed ID: 16474404
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comprehensive genetic analysis of overlapping syndromes of RAS/RAF/MEK/ERK pathway.
    Tumurkhuu M; Saitoh M; Sato A; Takahashi K; Mimaki M; Takita J; Takeshita K; Hama T; Oka A; Mizuguchi M
    Pediatr Int; 2010 Aug; 52(4):557-62. PubMed ID: 20030748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Deletion of MAP2K2/MEK2: a novel mechanism for a RASopathy?
    Nowaczyk MJ; Thompson BA; Zeesman S; Moog U; Sanchez-Lara PA; Magoulas PL; Falk RE; Hoover-Fong JE; Batista DA; Amudhavalli SM; White SM; Graham GE; Rauen KA
    Clin Genet; 2014 Feb; 85(2):138-46. PubMed ID: 23379592
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Costello syndrome and related disorders.
    Quezada E; Gripp KW
    Curr Opin Pediatr; 2007 Dec; 19(6):636-44. PubMed ID: 18025929
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Craniofacial and dental development in Costello syndrome.
    Goodwin AF; Oberoi S; Landan M; Charles C; Massie JC; Fairley C; Rauen KA; Klein OD
    Am J Med Genet A; 2014 Jun; 164A(6):1425-30. PubMed ID: 24668879
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A cardio-facio-cutaneous syndrome case with tight Achilles tendons.
    Hazan F; Aykut A; Hizarcioglu M; Tavli V; Onay H; Ozkinay F
    Genet Couns; 2012; 23(2):305-11. PubMed ID: 22876591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Genetics. Biobank ties cancer genes to rare developmental syndrome.
    Vogel G
    Science; 2006 Jan; 311(5760):456. PubMed ID: 16439635
    [No Abstract]   [Full Text] [Related]  

  • 39. Hyperactive Ras in developmental disorders and cancer.
    Schubbert S; Shannon K; Bollag G
    Nat Rev Cancer; 2007 Apr; 7(4):295-308. PubMed ID: 17384584
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ras/MAPK dysregulation in development causes a skeletal myopathy in an activating Braf
    Maeda Y; Tidyman WE; Ander BP; Pritchard CA; Rauen KA
    Dev Dyn; 2021 Aug; 250(8):1074-1095. PubMed ID: 33522658
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.